-
Phase III Trial Showed Investigational Compound Arzoxifene Was Superior To Evista (raloxifene HCl) In Increasing BMD In Postmenopausal Women With Osteoporosis
3/24/2009
Eli Lilly and Company presented new data showing arzoxifene, an investigational selective estrogen receptor modulator (SERM), was superior to raloxifene at increasing bone mineral density (BMD) in the lumbar spine, total hip and femoral neck, and at suppressing bone turnover as assessed by serum markers of bone metabolism.
-
U.S. FDA Advisory Committee Supports Favorable Benefit-Risk Profile Of Bayer's Rivaroxaban
3/20/2009
An Advisory Committee to the U.S. Food and Drug Administration (FDA) met today to discuss the new drug application (NDA) for Bayer’s rivaroxaban, a novel, oral anticoagulant taken as one tablet, once-daily for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery.
-
Biotechnology Center Promotes Drug Discovery Effort With $100,000 Planning Grant
3/19/2009
Planning for a virtual Center of Innovation that aims to get products from research labs to market more quickly is getting started with a $100,000 award from the North Carolina Biotechnology Center.
-
Herceptin Now Shown To Significantly Prolong The Lives Of Patients With HER2-Positive Advanced Stomach Cancer
3/19/2009
Roche recently announced results from a major international study which show that adding Herceptin (trastuzumab) to standard chemotherapy significantly prolongs lives of patients with HER2-positive stomach (gastric) cancer.
-
Herceptin Proven To Benefit Women With HER2 Positive Early Breast Cancer - Latest Results From The HERA Study
3/12/2009
The Breast International Group (BIG) in collaboration with Roche announced recently that women with HER2 positive early breast cancer continue to benefit from Herceptin (trastuzumab) several years after treatment completion and as a result enjoy a longer life disease free. The patients were treated for one year with Herceptin and followed up for four years.
-
Phase III Study Of Rituxan In Lupus Nephritis Did Not Meet Primary Endpoint
3/12/2009
Genentech, Inc. and Biogen Idec announced recently that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.
-
Merck To Buy Schering-Plough For $41.1 Billion
3/9/2009
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction.
-
Bristol-Myers Squibb Enters Global Collaboration With Nissan Chemical And Teijin Pharma On Novel Atrial Fibrillation Compound
3/5/2009
Bristol-Myers Squibb Company recently announced a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Limited for the development and commercialization of NTC-801, a selective inhibitor of the acetylcholine-activated potassium ion channel (IKACh), currently in Phase I development in Japan, for the maintenance of normal sinus rhythm in patients with atrial fibrillation.
-
NICE Recommends Xarelto® (Rivaroxaban) Use in NHS
3/5/2009
The National Institute for Health and Clinical Excellence (NICE) has issued an initial positive opinion on the new oral anticoagulant Xarelto(R) for the prevention of potentially fatal blood clots after elective hip or knee replacement surgery. The Scottish Medicines Consortium (SMC) has already accepted rivaroxaban for use in NHS Scotland.
-
MabThera Approved In The EU For Patients With Chronic Lymphocytic Leukaemia
3/3/2009
Roche announced recently that the European Commission has approved MabThera (rituximab) in combination with chemotherapy for use in patients with previously-untreated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia to affect adults.
